TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT04486352: A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

Sponsor: Alliance Foundation Trials, LLC. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 148 pts

Competing Trials Overlap

13 Active Trials

Excess Burn Exposure

$2,788,170

Rescue Site Savings

+$1,845,690

Unlock Full NCT04486352 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04486352 Rescue Dossier →